{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-081445","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.513320+00:00","generated_at":"2026-06-17T13:12:48.675484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acrivon Therapeutics reports FY 2022 net loss $31.2M, cash runway into Q4 2024","bullets":["Net loss for FY 2022 was $31.2M vs $16.2M in 2021; Q4 net loss $8.9M vs $4.3M.","R&D expenses $23.9M in 2022, driven by ACR-368 Phase 2 trial and companion diagnostic agreement.","Cash, cash equivalents and marketable securities $169.6M as of Dec 31, 2022; expected to fund operations at least into Q4 2024.","FDA clearance received for IND of ACR-368 Phase 2 trial in platinum-resistant ovarian, endometrial, and urothelial cancers.","Initial Phase 2 data expected in second half of 2023; WEE1 and PKMYT1 programs advancing toward IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-081445","json":"https://secwatch.observer/filing/0001193125-23-081445.json","markdown":"https://secwatch.observer/filing/0001193125-23-081445.md","text":"https://secwatch.observer/filing/0001193125-23-081445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/0001193125-23-081445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/d464039d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:12:48.675484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23f4a267cb2761bafafc7a777ad8482f8ecdb169","claim":"Acrivon Therapeutics, Inc. reported the full year ended December 31, 2022 results: net income $31.2 million.","evidence_excerpt":"Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/0001193125-23-081445-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"$31.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5590b1a4c7e90e773730a547381b4defc32ea290","claim":"Acrivon Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.9 million.","evidence_excerpt":"Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/0001193125-23-081445-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"$8.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}